Wegovy is approved for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity, such as high blood pressure or type 2 diabetes
Thyroid considerations apply to Retatrutide as they do to all GLP-1 class medications
When your digestive system is working harder to process food through a slower system, more energy gets directed to digestion, which can contribute to the fatigue some people experience on GLP-1 medications
For example, palm oil is high in saturated fat, which There are also some indirect public health effects of palm oil
In a major clinical trial, adults taking the 25-milligram (mg) Wegovy pill lost about 14% of their body weight over 64 weeks
GLP-1 Receptor Agonists (e.g., semaglutide, liraglutide) Increase insulin secretion in response to food Reduce glucagon release (which lowers blood sugar) Slows gastric emptying (which helps with post-meal glucose excursions) Reduces appetite and induces satiety which leads to weight loss GLP-1/GIP Receptor Agonists (e.g., tirzepatide) GLP-1 effects (same as above) GIP effect: further enhances insulin secretion Both medications help with blood sugar control and weight loss, but Mounjaros dual mechanism may offer stronger effects on insulin secretion, which improves A1c levels
